Kalvista Pharmaceuticals,

KalVista Pharmaceuticals is a biopharmaceutical company developing oral medicines designed to empower people to enjoy everyday life beyond the challenge of their disease. We apply our expertise to discover, develop and commercialize oral protease inhibitor drugs based on deep expertise in the kallikrein-kinin system. Our commitment to rigorous science is driven by our determination to better address treatment needs for patients, beginning with sebetralstat, our first investigational product for hereditary angioedema (HAE), a rare genetic disease with debilitating attacks of tissue swelling that can be life threatening.